Review recent studies that have characterized the benefits of integrated palliative care in hematologic malignancies
Explain what features of integrated palliative care lead to improved outcomes in hematologic malignancies
A 62-year-old man is diagnosed with acute myeloid leukemia (AML). Molecular genetic testing reveals an NPM1 mutation without FLT3 mutation. He undergoes induction chemotherapy with cytarabine/daunorubicin with a complete response, followed by consolidation with high-dose cytarabine, but has a persisting NPM1 mutation by quantitative polymerase chain reaction testing. Ultimately, a matched unrelated donor hematopoietic stem cell transplant (HSCT) is offered with curative intent. He is admitted to the hospital for conditioning chemotherapy with busulfan/cyclophosphamide. Palliative care (PC) consultation is offered to the patient. Do patients undergoing HSCT benefit from PC during their initial transplant hospitalization?
The integration of PC in hematologic malignancies has lagged behind solid oncology for many...